Trial · NCT01079663

The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis

NCT01079663, Phase 2, Completed, Dexcel Pharma Technologies Ltd.; results first posted 2021-06-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis. Trials, record NCT01079663. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01079663

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis
NCT number: NCT01079663
Status: Completed
Phases: Phase 2
Enrollment: 60 participants, actual
Lead sponsor: Dexcel Pharma Technologies Ltd.
Conditions: Peri-implantitis
Interventions: Chlorhexidine 2.5 mg, Placebo chip
First posted: 2010-03-03
Last updated: 2021-06-15
Results first posted: 2021-06-15

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket	Baseline to Week 24	Pocket depth is the measurement of the distance from the coronal edge of the gingival margin to the base of the pocket. Measurements were taken with a standard 15-mm University of North Carolina (UNC) periodontal probe. Change from baseline in PPD was calculated as Week 24 PPD minus Baseline PPD such that a negative difference indicates an improvement in condition
Secondary	Clinical Attachment Levels (CAL)	Baseline to Week 24	Loss of attachment is defined as the distance in millimetres that the base of the pocket has migrated apically from the gingival margin of the crown. CAL was calculated at the same site that PPD was measured
Secondary	Bleeding on Probing (BOP)	Baseline to Week 24	BOP was measured at the same site after measuring the PPD. The scoring system used for recording the BOP was a dichotomous one: 0 = No bleeding 1 = Bleeding on probing of the pocket base

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket	Baseline to Week 24	mm	MEAN
SECONDARY	Clinical Attachment Levels (CAL)	Baseline to Week 24	mm	MEAN
SECONDARY	Bleeding on Probing (BOP)	Baseline to Week 24	Target implant	COUNT_OF_UNITS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket	Chlorhexidine Chip (Periochip®)	-2.13	Standard Deviation 1.399	mm
Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket	Placebo Chip	-1.79	Standard Deviation 1.149	mm
Clinical Attachment Levels (CAL)	Chlorhexidine Chip (Periochip®)	-2.18	Standard Deviation 1.394	mm
Clinical Attachment Levels (CAL)	Placebo Chip	-1.76	Standard Deviation 1.257	mm
Bleeding on Probing (BOP)	Chlorhexidine Chip (Periochip®)	23		Target implant
Bleeding on Probing (BOP)	Placebo Chip	16		Target implant

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Chlorhexidine Chip (Periochip®)	30
Overall Study	STARTED	Placebo Chip	30
Overall Study	COMPLETED	Chlorhexidine Chip (Periochip®)	30
Overall Study	COMPLETED	Placebo Chip	26
Overall Study	NOT COMPLETED	Chlorhexidine Chip (Periochip®)	0
Overall Study	NOT COMPLETED	Placebo Chip	4

Source ClinicalTrials.gov

Adverse events24

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Aphthous ulcer	Gastrointestinal disorders	Chlorhexidine Chip (Periochip®)	1	30
other	Aphthous ulcer	Gastrointestinal disorders	Placebo Chip	2	30
other	Gingival swelling	Gastrointestinal disorders	Chlorhexidine Chip (Periochip®)	3	30
other	Gingival swelling	Gastrointestinal disorders	Placebo Chip	0	30
other	Periodontal disease	Gastrointestinal disorders	Chlorhexidine Chip (Periochip®)	3	30
other	Periodontal disease	Gastrointestinal disorders	Placebo Chip	0	30
other	Periodontal inflammation	Gastrointestinal disorders	Chlorhexidine Chip (Periochip®)	0	30
other	Periodontal inflammation	Gastrointestinal disorders	Placebo Chip	3	30
other	Toothache	Gastrointestinal disorders	Chlorhexidine Chip (Periochip®)	0	30
other	Toothache	Gastrointestinal disorders	Placebo Chip	2	30

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Chlorhexidine Chip (Periochip®)	0	30
Total, all-cause mortality	Placebo Chip	0	30
Total, other adverse events	Chlorhexidine Chip (Periochip®)	15	30
Total, other adverse events	Placebo Chip	16	30
Total, serious adverse events	Chlorhexidine Chip (Periochip®)	0	30
Total, serious adverse events	Placebo Chip	2	30

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Chlorhexidine Chip (Periochip®) vs Placebo Chip: deaths from any cause	Trial comparisons
Chlorhexidine Chip (Periochip®) vs Placebo Chip: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01079663

GET https://conductscience.org/api/trials/v1/NCT01079663/events?page=2

API reference For AI assistants